ARK001 is a novel investigational treatment with a proprietary formulation for the treatment of infantile hemangioma (IH)
ARK001: A Novel Investigational Product Designed to Treat IH
Pediatric-specific formulation— Clear topical gel designed for sensitive skin
Topical delivery— Applied directly to the IH where it is absorbed to act locally
Ultra-short half-life— The active ingredient, esmolol, is rapidly metabolized locally by red blood cells; no systemic beta blockade
Less risk of hypoglycemia – can be administered without food/no need to wake a baby for feeding
Low expected risk of side effects seen with other beta blockers
Esmolol is beta-1 selective, and topical administration in animal models results in blood levels that are inadequate to induce systemic beta blockade
Intended to reduce risk of bradycardia or wheezing
Intended to reduce risk of CNS side effects such as sleep disturbance or negative cognitive impact
